Public funding and pricing
Public funding and pricing The Norwegian Medical Products Agency is responsible for setting maximum prices on prescription-only-medicines. The Agency also evaluates and decides whether a medicine should be publicly funded.
The Norwegian Medical Products Agency is responsible for setting maximum prices on prescription-only-medicines. The Agency also evaluates and decides whether a medicine should be publicly funded.
FINOSE becomes Joint Nordic HTA-Bodies, JNHB
Published:
FINOSE now includes all Nordic countries
Published:
Switching between a reference product and a biosimilar
Published:
|
Updated:
FINOSE collaboration prolonged and strengthened by entry of the Danish Medicines Council
Published:
|
Updated: